OUR PARTNERS IN THE LEIBNIZ RESEARCH ALLIANCE „HEALTH TECHNOLOGIES“
Leibniz Institute of Photonic Technology Jena (Leibniz IPHT) Ferdinand-Braun-Institut − Leibniz Institute PREVENTION. for High Frequency Technology (FBH) DIAGNOSIS. Innovations for High Perfomance Microelectronics (IHP) THERAPY.
Leibniz-Center for Medicine and Biosciences, Research Center Borstel (FZB) LEIBNIZ HEALTH TECHNOLOGIES Leibniz Institute for Analytical Sciences (ISAS) Office: Leibniz Research Centre for Working Environment Philosophenweg 7 and Human Factors (IfADo) 07743 Jena
Leibniz Institute for Astrophysics Potsdam Address: (AIP, associated) PO Box 100 239 D-07702 Jena Leibniz Institute for Interactive Materials (DWI) Phone: 0049 3641 948 362 Leibniz Institute for Natural Product Research and Infection Biology − Hans Knöll Institute (HKI) Fax: 0049 3641 948 302 Leibniz Institute for New Materials (INM) [email protected] Leibniz Institute of Plasma Science www.leibniz-healthtech.de and Technology (INP) Speaker: Leibniz Institute for Polymer Research Dresden Prof. Dr. Jürgen Popp (IPF)
Weierstrass Institute for Applied Analysis and Stochastics (WIAS)
Associated Industrial Partners: ▪ Biophotonics Diagnostics GmbH ▪ neoplas tools GmbH THE COMPETENCE AREAS OUR COMPETENCE AREAS BIOMARKERS OF THE RESEARCH ALLIANCE Objective parameters for The partners in the Leibniz Research Alliance successful individualized therapy “Health Technologies” have defined five interdisci- plinary competence areas as central research pillars, The scientists in the competence area “Biomarkers” all of which pursue a common goal: To apply results are exploring the early detection of common User Benefit & Acceptance of New Technologies of fundamental research as quickly and efficiently as diseases such as dementia, cancer, myocardial possible for use as medical technologies. infarction or stroke. For this they use biomarkers: Data Management & IP Regulation These are objective parameters of the patient, INDUSTRY POLITICS which are clearly related to disease stages − Economic & Social Consequences comparable to a blood glucose test for diabetes. HEALTH CLINICS INSURANCES
VENTURE CAPITALISTS GOVERNMENT AGENCIES POINT-OF-CARE TECHNOLOGIES PLASMA MEDICINE MEDICAL ASSOCIATIONS Reliable diagnoses Preventive care and within minutes personalized medical treatment
Novel point-of-care procedures (PoC) should Artificially produced, so-called “cold” plasmas LEIBNIZ HEALTH TECHNOLOGIES facilitate a risk assessment of widespread diseases have attracted attention in the past few years for A research alliance of the Leibniz Association within a few minutes − ideally for several diseases applications in medicine. The reason: They kill at the same time. The aim is to provide fast and microorganisms while sparing healthy tissue and Concrete technology solutions for urgent medical reliable diagnostics with easy-to-obtain samples (for allow a targeted stimulation of cell growth. Plas- questions − this is the main focus of the 13 member example saliva, urine or tear fluid). This is expected mas are therefore already used today for wound institutes of the research alliance Leibniz Health to save costs and provide the patient with a more healing and for the prevention of infections. The Technologies. gentle screening method. scientists in the competence area of plasma med- icine develop therapeutic approaches further and Together with industry partners they are pursuing the explore new medical applications. goal of improving medical care for patients. Through an interdisci plinary approach prevention, diagnosis and therapy shall grow together and thus increase IMAGING METHODS BIOACTIVE MATERIALS the quality of life. The alliance combines Fast detection and Functional materials for competencies from various fields: From photonics precise disease control state-of-the-art medical technology and medicine to microelectronics and material research, to economic research and applied mathe- In this competence area, Leibniz researchers Whether hydrogels, organ replacement systems, or matics. In close coordination with industry, hospitals, concentrate on high-sensitivity optical technol- stents in blood vessels − modern medicine depends insurance companies and politicians the research ogies that allow, for example, surgical interven- on functional materials and surfaces. Thus, Leibniz alliance develops health care technologies that tions to be precisely monitored in real-time. The Health Technologies is investigating materials are brought to market along a seamless innovation combination of innovative microscopy techniques that can be integrated well into the organism and chain. In parallel, Leibniz Health Technologies with spectroscopic methods allows unique insights prevent colonization with germs.Leibniz scientists investigates the social and economic consequences of into the three-dimensional structure and chemical develop bioactive surfaces which stimulate cells, new medical technologies in order to optimize their composition of individual cells up to organs − even release active substances and regulate healing usefulness for the user and to create broad social without having to label the tissue beforehand. processes. acceptance for new technologies.